Thromb Haemost 2023; 123(01): 123-130
DOI: 10.1055/s-0042-1760263
Editors' Choice

Thrombosis and Haemostasis 2022 Editors' Choice Papers

Christian Weber
1   Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany
2   German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Munich, Germany
3   Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre, Maastricht, The Netherlands
Xavier Blanchet
1   Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany
Gregory Y. H. Lip
4   Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom
5   Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
› Author Affiliations

The Editor's Choice from Thrombosis and Haemostasis as well as from its open access companion journal TH Open highlights the articles and reviews of the year that have achieved the greatest resonance among our readers. In 2022, the coronavirus disease 2019 (COVID-19) has remained an important topic mandating the need to interrogate the emergence and management of new viral infections.[1] Several of our most highly cited papers have dealt with bleeding and thrombotic complications, their diagnosis, and management in several pathologies, including cancer and pulmonary and COVID-19-associated cardiovascular diseases (CVDs).[2] [3] [4] [5] [6] Particular interest was also instigated by a new promising concept of the holistic or integrated care management approach of patients with stroke along with the definition of an “aortovascular hub” aligned with an integrated health care system.[7] [8]

Publication History

Article published online:
10 January 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

  • References

  • 1 Iba T, Levy JH, Levi M. Viral-induced inflammatory coagulation disorders: preparing for another epidemic. Thromb Haemost 2022; 122 (01) 8-19
  • 2 Romiti GF, Pastori D, Rivera-Caravaca JM. et al. Adherence to the 'Atrial Fibrillation Better Care' pathway in patients with atrial fibrillation: impact on clinical outcomes-a systematic review and meta-analysis of 285,000 patients. Thromb Haemost 2022; 122 (03) 406-414
  • 3 Chao T-F, Joung B, Takahashi Y. et al. 2021 Focused update consensus guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: executive summary. Thromb Haemost 2022; 122 (01) 20-47
  • 4 Bikdeli B, Talasaz AH, Rashidi F. et al. Intermediate-dose versus standard-dose prophylactic anticoagulation in patients with COVID-19 admitted to the intensive care unit: 90-day results from the INSPIRATION randomized trial. Thromb Haemost 2022; 122 (01) 131-141
  • 5 Marcos-Jubilar M, Carmona-Torre F, Vidal R. et al; BEMICOP Investigators. Therapeutic versus prophylactic bemiparin in hospitalized patients with nonsevere COVID-19 pneumonia (BEMICOP study): an open-label, multicenter, randomized, controlled trial. Thromb Haemost 2022; 122 (02) 295-299
  • 6 Agnelli G, Muñoz A, Franco L. et al. Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thromb Haemost 2022; 122 (05) 796-807
  • 7 Field M, Kuduvalli M, Torella F, McKay V, Khalatbari A, Lip GYH. Integrated care systems and the aortovascular hub. Thromb Haemost 2022; 122 (02) 177-180
  • 8 Lip GYH, Ntaios G. “Novel Clinical Concepts in Thrombosis”: integrated care for stroke management-easy as ABC. Thromb Haemost 2022; 122 (03) 316-319
  • 9 Klug M, Lazareva O, Kirmes K. et al. Platelet surface protein expression and reactivity upon TRAP stimulation after BNT162b2 vaccination. Thromb Haemost 2022; 122 (10) 1706-1711
  • 10 Rodríguez-Pardo J, Gilo-Arrojo F, Ruiz-Ares G. et al. Thrombosis and thrombocytopenia syndrome causing isolated symptomatic carotid occlusion after covid-19 vaccine. Thromb Haemost 2022; 122 (02) 300-303
  • 11 Lindhoff-Last E, Schoenborn L, Piorkowski M. et al. Heterogeneity of vaccine-induced immune thrombotic thrombocytopenia after ChAdOx1 nCoV-19 vaccination and safety of second vaccination with BNT162b2. Thromb Haemost 2022; 122 (02) 304-307
  • 12 von Hundelshausen P, Lorenz R, Siess W, Weber C. Vaccine-induced immune thrombotic thrombocytopenia (VITT): targeting pathomechanisms with Bruton tyrosine kinase inhibitors. Thromb Haemost 2021; 121 (11) 1395-1399
  • 13 Melkumyants A, Buryachkovskaya L, Lomakin N, Antonova O, Serebruany V. Mild COVID-19 and impaired blood cell-endothelial crosstalk: considering long-term use of antithrombotics?. Thromb Haemost 2022; 122 (01) 123-130
  • 14 Traby L, Kollars M, Kussmann M. et al. Extracellular vesicles and citrullinated histone H3 in coronavirus disease 2019 patients. Thromb Haemost 2022; 122 (01) 113-122
  • 15 Blasco A, Coronado M-J, Vela P. et al. Prognostic implications of neutrophil extracellular traps in coronary thrombi of patients with ST-elevation myocardial infarction. Thromb Haemost 2022; 122 (08) 1415-1428
  • 16 Gorog DA, Storey RF, Gurbel PA. et al. Current and novel biomarkers of thrombotic risk in COVID-19: a consensus statement from the International COVID-19 Thrombosis Biomarkers Colloquium. Nat Rev Cardiol 2022; 19 (07) 475-495
  • 17 Mei F, Fan J, Yuan J. et al. Comparison of venous thromboembolism risks between COVID-19 pneumonia and community-acquired pneumonia patients. Arterioscler Thromb Vasc Biol 2020; 40 (09) 2332-2337
  • 18 Cangemi R, Calvieri C, Falcone M. et al. Comparison of thrombotic events and mortality in patients with community-acquired pneumonia and COVID-19: a multicenter observational study. Thromb Haemost 2022; 122 (02) 257-266
  • 19 Fumagalli S, Trevisan C, Del Signore S. et al; GeroCovid Working Group. COVID-19 and atrial fibrillation in older patients: does oral anticoagulant therapy provide a survival benefit?-An insight from the GeroCovid registry. Thromb Haemost 2022; 122 (01) 105-112
  • 20 Lip GYH. The ABC pathway: an integrated approach to improve AF management. Nat Rev Cardiol 2017; 14 (11) 627-628
  • 21 Weber C, Rigby A, Lip GYH. Thrombosis and Haemostasis 2021 Editors' Choice Papers. Thromb Haemost 2022; 122 (01) 163-170
  • 22 Kim HK, Tantry US, Smith Jr SC. et al. The East Asian Paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease. Thromb Haemost 2021; 121 (04) 422-432
  • 23 Gorog DA, Gue YX, Chao TF. et al. Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: executive summary of a European and Asia-Pacific Expert Consensus Paper. Thromb Haemost 2022; 122 (10) 1625-1652
  • 24 Kirchhof P, Camm AJ, Goette A. et al; EAST-AFNET 4 Trial Investigators. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med 2020; 383 (14) 1305-1316
  • 25 Chao T-F, Chan Y-H, Chiang C-E. et al. Early rhythm control and the risks of ischemic stroke, heart failure, mortality, and adverse events when performed early (<3 months): a nationwide cohort study of newly diagnosed patients with atrial fibrillation. Thromb Haemost 2022; 122 (11) 1899-1910
  • 26 Kim D, Yang PS, You SC. et al. Comparative effectiveness of early rhythm control versus rate control for cardiovascular outcomes in patients with atrial fibrillation. J Am Heart Assoc 2021; 10 (24) e023055
  • 27 Sun W, Freedman B, Martinez C, Wallenhorst C, Yan BP. Atrial fibrillation detected by single time-point handheld electrocardiogram screening and the risk of ischemic stroke. Thromb Haemost 2022; 122 (02) 286-294
  • 28 Wallenhorst C, Martinez C, Freedman B. Risk of ischemic stroke in asymptomatic atrial fibrillation incidentally detected in primary care compared with other clinical presentations. Thromb Haemost 2022; 122 (02) 277-285
  • 29 Kitsiou A, Rogalewski A, Kalyani M. et al. Atrial fibrillation in patients with embolic stroke of undetermined source during 3 years of prolonged monitoring with an implantable loop recorder. Thromb Haemost 2021; 121 (06) 826-833
  • 30 Kalarus Z, Mairesse GH, Sokal A. et al. Searching for atrial fibrillation: looking harder, looking longer, and in increasingly sophisticated ways. An EHRA position paper'. Europace 2022; (e-pub ahead of print) DOI: 10.1093/europace/euac144.
  • 31 Proietti M, Boriani G. Screening for atrial fibrillation in relation to stroke and mortality risk. Thromb Haemost 2022; 122 (02) 171-175
  • 32 Jones NR, Crawford W, Yang Y, Hobbs FDR, Taylor CJ, Petrou S. A systematic review of economic aspects of service interventions to increase anticoagulation use in atrial fibrillation. Thromb Haemost 2022; 122 (03) 394-405
  • 33 Ivany E, Lotto RR, Lip GYH, Lane DA. Managing uncertainty: physicians' decision making for stroke prevention for patients with atrial fibrillation and intracerebral hemorrhage. Thromb Haemost 2022; 122 (09) 1603-1611
  • 34 Nelson AJ, Johnston BW, Waite AAC, Lemma G, Welters ID. A systematic review of anticoagulation strategies for patients with atrial fibrillation in critical care. Thromb Haemost 2021; 121 (12) 1599-1609
  • 35 Romiti GF, Proietti M, Bonini N. et al; GLORIA-AF Investigators. Clinical complexity domains, anticoagulation, and outcomes in patients with atrial fibrillation: a report from the GLORIA-AF registry phase II and III. Thromb Haemost 2022; 122 (12) 2030-2041
  • 36 Camelo-Castillo A, Rivera-Caravaca JM, Marín F, Vicente V, Lip GYH, Roldán V. Predicting adverse events beyond stroke and bleeding with the ABC-stroke and ABC-bleeding scores in patients with atrial fibrillation: the Murcia AF project. Thromb Haemost 2020; 120 (08) 1200-1207
  • 37 Cohen AT, Katholing A, Rietbrock S, Bamber L, Martinez C. Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study. Thromb Haemost 2017; 117 (01) 57-65
  • 38 Bonnesen K, Schmidt M, Horváth-Puhó E, Sørensen HT. The interaction effect between comorbidity burden and venous thromboembolism on mortality: a nationwide cohort study. Thromb Haemost 2022; 122 (04) 578-589
  • 39 de Winter MA, Dorresteijn JAN, Ageno W. et al. Estimating bleeding risk in patients with cancer-associated thrombosis: evaluation of existing risk scores and development of a new risk score. Thromb Haemost 2022; 122 (05) 818-829
  • 40 Girard P, Laporte S, Chapelle C. et al. Failure of the Ottawa Score to predict the risk of recurrent venous thromboembolism in cancer patients: the prospective PREDICARE cohort study. Thromb Haemost 2022; 122 (01) 151-157
  • 41 Riedl JM, Schwarzenbacher E, Moik F. et al. Patterns of thromboembolism in patients with advanced pancreatic cancer undergoing first-line chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel. Thromb Haemost 2022; 122 (04) 633-645
  • 42 Ow T-W, Fatourou E, Rabinowich L. et al. Prevalence of bleeding and thrombosis in critically ill patients with chronic liver disease. Thromb Haemost 2022; 122 (06) 1006-1016
  • 43 Cohen AT, Sah J, Dhamane AD. et al. Effectiveness and safety of apixaban versus warfarin in venous thromboembolism patients with chronic kidney disease. Thromb Haemost 2022; 122 (06) 926-938
  • 44 Bertoletti L, Gusto G, Khachatryan A. et al. Effectiveness and safety of oral anticoagulants in the treatment of acute venous thromboembolism: a nationwide comparative cohort study in France. Thromb Haemost 2022; 122 (08) 1384-1396
  • 45 Mahé I, Agnelli G, Ay C. et al. Extended anticoagulant treatment with full- or reduced-dose apixaban in patients with cancer-associated venous thromboembolism: rationale and design of the API-CAT study. Thromb Haemost 2022; 122 (04) 646-656
  • 46 Meyer G, Vicaut E, Danays T. et al; PEITHO Investigators. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med 2014; 370 (15) 1402-1411
  • 47 Sanchez O, Charles-Nelson A, Ageno W. et al; PEITHO-3 Investigators. Reduced-dose intravenous thrombolysis for acute intermediate-high-risk pulmonary embolism: rationale and design of the Pulmonary Embolism International THrOmbolysis (PEITHO)-3 trial. Thromb Haemost 2022; 122 (05) 857-866
  • 48 Kim H-S, Kang J, Hwang D. et al; HOST-REDUCE-POLYTECH-ACS investigators. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial. Lancet 2020; 396 (10257): 1079-1089
  • 49 Lee HS, Park KW, Kang J, Han JK, Kim HS. De-escalation of prasugrel results in higher percentage of patients within optimal range of platelet reactivity: analysis from the HOST-REDUCE-POLYTECH-ACS trial. Thromb Haemost 2022; 122 (01) 160-162
  • 50 Davidson KW, Barry MJ, Mangione CM. et al; US Preventive Services Task Force. Aspirin use to prevent cardiovascular disease: US Preventive Services Task Force recommendation statement. JAMA 2022; 327 (16) 1577-1584
  • 51 Calderone D, Greco A, Ingala S. et al. Efficacy and safety of aspirin for primary cardiovascular risk prevention in younger and older age: an updated systematic review and meta-analysis of 173,810 subjects from 21 randomized studies. Thromb Haemost 2022; 122 (03) 445-455
  • 52 Tullemans BME, Fernández DI, Veninga A. et al. Tyrosine kinase inhibitor sunitinib delays platelet-induced coagulation: additive effects of aspirin. Thromb Haemost 2022; 122 (01) 92-104
  • 53 Bovenschen N, Rijken DC, Havekes LM, van Vlijmen BJ, Mertens K. The B domain of coagulation factor VIII interacts with the asialoglycoprotein receptor. J Thromb Haemost 2005; 3 (06) 1257-1265
  • 54 Steirer LM, Park EI, Townsend RR, Baenziger JU. The asialoglycoprotein receptor regulates levels of plasma glycoproteins terminating with sialic acid α2,6-galactose. J Biol Chem 2009; 284 (06) 3777-3783
  • 55 Lunghi B, Morfini M, Martinelli N. et al. The asialoglycoprotein receptor minor subunit gene contributes to pharmacokinetics of factor VIII concentrates in hemophilia A. Thromb Haemost 2022; 122 (05) 715-725
  • 56 Ichinose A, Osaki T, Souri M. Autoimmune coagulation factor X deficiency as a rare acquired hemorrhagic disorder: a literature review. Thromb Haemost 2022; 122 (03) 320-328
  • 57 Sharman Moser S, Chodick G, Ni YG. et al. The association between factor XI deficiency and the risk of bleeding, cardiovascular, and venous thromboembolic events. Thromb Haemost 2022; 122 (05) 808-817
  • 58 Preis M, Hirsch J, Kotler A. et al. Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events. Blood 2017; 129 (09) 1210-1215
  • 59 Connolly SJ, Crowther M, Eikelboom JW. et al; ANNEXA-4 Investigators. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med 2019; 380 (14) 1326-1335
  • 60 Benz AP, Xu L, Eikelboom JW. et al; ANNEXA-4 Investigators. Andexanet alfa for specific anticoagulation reversal in patients with acute bleeding during treatment with edoxaban. Thromb Haemost 2022; 122 (06) 998-1005
  • 61 Tsantes AG, Papadopoulos DV, Trikoupis IG. et al. The prognostic performance of rotational thromboelastometry for excessive bleeding and increased transfusion requirements in hip fracture surgeries. Thromb Haemost 2022; 122 (06) 895-904
  • 62 Margetić S, Ćelap I, Huzjan AL. et al. DOAC dipstick testing can reliably exclude the presence of clinically relevant DOAC concentrations in circulation. Thromb Haemost 2022; 122 (09) 1542-1548
  • 63 Navarese EP, Grisafi L, Spinoni EG. et al. Safety and efficacy of different antithrombotic strategies after transcatheter aortic valve implantation: a network meta-analysis. Thromb Haemost 2022; 122 (02) 216-225
  • 64 Chappell J, Harman JL, Narasimhan VM. et al. Extensive proliferation of a subset of differentiated, yet plastic, medial vascular smooth muscle cells contributes to neointimal formation in mouse injury and atherosclerosis models. Circ Res 2016; 119 (12) 1313-1323
  • 65 Padfield GJ, Newby DE, Mills NL. Understanding the role of endothelial progenitor cells in percutaneous coronary intervention. J Am Coll Cardiol 2010; 55 (15) 1553-1565
  • 66 Mause SF, Ritzel E, Deck A, Vogt F, Liehn EA. Endothelial progenitor cells modulate the phenotype of smooth muscle cells and increase their neointimal accumulation following vascular injury. Thromb Haemost 2022; 122 (03) 456-469
  • 67 Field ML, Kuduvalli M, Torella F, Lip GY. Aortovascular medicine: what is it?. J R Soc Med 2021; 114 (10) 467-469
  • 68 Kamel H, Okin PM, Elkind MSV, Iadecola C. Atrial fibrillation and mechanisms of stroke: time for a new model. Stroke 2016; 47 (03) 895-900
  • 69 Lip GYH, Lane DA, Lenarczyk R. et al. Integrated care for optimizing the management of stroke and associated heart disease: a position paper of the European Society of Cardiology Council on Stroke. Eur Heart J 2022; 43 (26) 2442-2460
  • 70 Guo Y. A new paradigm of “real-time” stroke risk prediction and integrated care management in the digital health era: innovations using machine learning and artificial intelligence approaches. Thromb Haemost 2022; 122 (01) 5-7
  • 71 Lip GYH, Genaidy A, Tran G, Marroquin P, Estes C, Sloop S. Improving stroke risk prediction in the general population: a comparative assessment of common clinical rules, a new multimorbid index, and machine-learning-based algorithms. Thromb Haemost 2022; 122 (01) 142-150
  • 72 Veninga A, Baaten CCFMJ, De Simone I. et al. Effects of platelet agonists and priming on the formation of platelet populations. Thromb Haemost 2022; 122 (05) 726-738
  • 73 King SL, Joshi HJ, Schjoldager KT. et al. Characterizing the O-glycosylation landscape of human plasma, platelets, and endothelial cells. Blood Adv 2017; 1 (07) 429-442
  • 74 Li R, Hoffmeister KM, Falet H. Glycans and the platelet life cycle. Platelets 2016; 27 (06) 505-511
  • 75 Zieger B, Boeckelmann D, Anani W. et al. Novel GNE gene variants associated with severe congenital thrombocytopenia and platelet sialylation defect. Thromb Haemost 2022; 122 (07) 1139-1146
  • 76 Pennings GJ, Reddel CJ, Traini M. et al. Rapid release of interleukin-1β from human platelets is independent of NLRP3 and caspase. Thromb Haemost 2022; 122 (04) 517-528
  • 77 Santovito D, Weber C. Non-canonical features of microRNAs: paradigms emerging from cardiovascular disease. Nat Rev Cardiol 2022; 19 (09) 620-638
  • 78 Pedersen OB, Grove EL, Kristensen SD, Nissen PH, Hvas AM. MicroRNA as biomarkers for platelet function and maturity in patients with cardiovascular disease. Thromb Haemost 2022; 122 (02) 181-195